Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma

PURPOSE: Glioblastoma (GBM) is an incurable primary brain tumor that has not benefited from immunotherapy to date. More than 90% of GBM expresses the tryptophan (Trp) metabolic enzyme, indoleamine 2,3-dioxygenase 1 (IDO). This observation supported the historical hypothesis that IDO suppresses the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Lijie, Bell, April, Ladomersky, Erik, Lauing, Kristen L., Bollu, Lakshmi, Nguyen, Brenda, Genet, Matthew, Kim, Miri, Chen, Peiwen, Mi, Xinlei, Wu, Jennifer D., Schipma, Matthew J., Wray, Brian, Griffiths, John, Unwin, Richard D., Clark, Simon J., Acharya, Rajesh, Bao, Riyue, Horbinski, Craig, Lukas, Rimas V., Schiltz, Gary E., Wainwright, Derek A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639612/
https://www.ncbi.nlm.nih.gov/pubmed/34479957
http://dx.doi.org/10.1158/1078-0432.CCR-21-1392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639612/
https://www.ncbi.nlm.nih.gov/pubmed/34479957
http://dx.doi.org/10.1158/1078-0432.CCR-21-1392

Ejemplares similares